Type-2-Diabetes: Canagliflozin reduces cardiovascular Risk

被引：0

|

作者：

Lichert, Frank

机构：

来源：

DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT | 2017年 / 142卷 / 22期

关键词：

D O I：

10.1056/NEJMoa.1611925

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：1647 / 1647

页数：1

相关论文

共 50 条

[41] Increasing Weight Fluctuations the Risk for Type-2-Diabetes? Comment
Hauner, Hans
DIABETOLOGIE UND STOFFWECHSEL, 2016, 11 (01) : 27 - 27
[42] Type-2-Diabetes in Adolescence
Pavlicek, V.
DIABETOLOGE, 2012, 8 (05): : 412 - 413
[43] Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes
Januzzi, James L.
Butler, Javed
Jarolim, Petr
Sattar, Naveed
Vijapurkar, Ujjwala
Desai, Mehul
Davies, Michael J.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 70 (06) : 704 - 712
[44] Does the Taking of Antidepressiva increase the Risk for Type-2-Diabetes?
Hermanns, N.
DIABETOLOGE, 2011, 7 (06): : 410 - 411
[45] Higher Dementia Risk with early onset type-2-Diabetes?
Weiss, Johannes
DIABETOLOGIE UND STOFFWECHSEL, 2017, 12 (01) : 21 - 21
[46] Type-2-diabetes: How can the risk be best determined?
Schwarz, Peter E. H.
Li, Jiang
DIABETOLOGIE UND STOFFWECHSEL, 2007, 2 (05) : 300 - 301
[47] Pioglitazone is superior to metformin or glibenclamide in recclucing markers of cardiovascular risk in patients with type-2-diabetes mellitus
Gulba, D
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (04) : 163A - 163A
[48] Oral Add-on Therapy to Metformin in Type-2-Diabetes mellitus: Canagliflozin and Sitagliptin in a direct Comparison
Schnell, O.
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2014, 139 : S70 - S74
[49] Is the Risk of Developing Type-2-Diabetes increased with Statin Treatment?
Chakaroun, R.
DIABETOLOGE, 2015, 11 (05): : 407 - 408
[50] "ePrevention" - rethinking cardiovascular Risk Management in Type-2-Diabetes mellitus - interdisciplinary, digitalized, personalized in PraeVaNet
Leistner, D. M.
DIABETES STOFFWECHSEL UND HERZ, 2021, 30 (06): : 392 - 396

← 1 2 3 4 5 →